STAT3-IN-1
Based on 11 publication(s) in Google Scholar
STAT3-IN-1 (compound 7d) is an excellent, selective and orally active STAT3 inhibitor, with IC50 values of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 (compound 7d) induces tumor cells apoptosis.
For research use only. We do not sell to patients.
- Purity: 96.28%
- CAS No.: 2059952-75-7
- Formula: C28H29NO6
- Molecular Weight:475.53
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
JAK/STAT Compound Library
HY-L008
-
Kinase Inhibitor Library
HY-L009
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Anti-Aging Compound Library
HY-L034
-
Covalent Screening Library
HY-L036
-
Differentiation Inducing Compound Library
HY-L038
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Obesity Compound Library
HY-L087
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Cancer Stem Cells Compound Library
HY-L135
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) STAT3-IN-1
More- Int J Oral Sci. 2025 Sep 12;17(1):64. [Abstract]
- Redox Biol. 2022 Oct:56:102461. [Abstract]
- Acta Pharm Sin B. 2023 Jun;13(6):2645-2662. [Abstract]
- Neurotherapeutics. 2025 Aug 5:e00709. [Abstract]
- Biochem Pharmacol. 2020 Oct;180:114126. [Abstract]
- Cancer Biol Ther. 2023 Dec 31;24(1):2271638. [Abstract]
- Cell Biol Toxicol. 2023 Dec;39(6):2821-2839. [Abstract]
- Cell Oncol (Dordr). 2025 Jun 12. [Abstract]
- Int Immunopharmacol. 2023 Jan:114:109561. [Abstract]
- Cell Biol Int. 2021 Oct;45(10):2054-2062. [Abstract]
- Research Square Print. 2022 May.
Customer Validation & Images
-
WB
Biological Activity
|
Stat-3 1.82 μM (IC50, in HT29 cells) |
Stat-3 2.14 μM (IC50, in MDA-MB 231 cells) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-29 | IC50 |
1.82 μM
Compound: 7d
|
Growth inhibition of human HT-29 cells after 48 hrs by MTT assay
Growth inhibition of human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 27783972] |
| MDA-MB-231 | IC50 |
2.14 μM
Compound: 7d
|
Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay
Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 27783972] |
STAT3-IN-1 (compound 7d: 0-10 μM, 48 h) inhibits the STAT3 acetylation at lysine 685 and affected its specific genes expressions[1].
?
STAT3-IN-1 (compound 7d: 0-10 μM, 48 h) induces tumor cells apoptosis in MDA-MB-231 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231 cell lines.
-
Concentration:0-10 μM.
-
Incubation Time:48 hours.
-
Result:The induced apoptosis rates (early and late apoptosis) at 1, 2, 5, 8 and 10 μM were 9.0%, 11.2%, 20.9%, 43.3% and 85.2% versus control 3.0%.
-
Cell Line:MDA-MB-231 and HT-29 cell lines.
-
Concentration:0-10 μM.
-
Incubation Time:48 hours.
-
Result:Inhibited STAT3 acetylation and STAT3 tyrosine phosphorylation in MDA-MB-231 cells.
Increased the expressions of these tumor-suppressor genes (PTPN6 (SHP-1), CDKN2A and DLEC1) which were related to STAT3 acetylation at Lys685.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mouse-xenograft model bearing inoculation of mice breast cancer 4T1 cells[1].
-
Dosage:10, 20 mg/kg.
-
Administration:Oral administration once every other day for two weeks.
-
Result:Arrested tumor growth with no obvious body weight loss.
Chemical Information
-
CAS No. 2059952-75-7
-
Appearance Solid
-
Molecular Weight 475.53
-
Formula C28H29NO6
-
Color Light yellow to orange
-
SMILES
COC1=CC(OC)=CC(/C=C/C2=CC=C(NC(/C=C/C3=CC(OC)=C(OC)C(OC)=C3)=O)C=C2)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Int J Oral Sci
LncRNA EUDAL shapes tumor cell response to hypoxia-induced constitutive EGFR activation and promotes chemoresistance in oral cancer. [Abstract]2025 Sep 12;17(1):64. PMID: 40940319 -
Redox Biol
HDAC11 negatively regulates antifungal immunity by inhibiting Nos2 expression via binding with transcriptional repressor STAT3. [Abstract]2022 Oct:56:102461. PMID: 36087429 -
Acta Pharm Sin B
The suppression of cervical cancer ferroptosis by macrophages: The attenuation of ALOX15 in cancer cells by macrophages-derived exosomes. [Abstract]2023 Jun;13(6):2645-2662. PMID: 37425043 -
Neurotherapeutics
Reticuline modulates astrocyte and microglial responses to enhance prognosis after traumatic brain injury. [Abstract]2025 Aug 5:e00709. PMID: 40769849 -
Biochem Pharmacol
Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE. [Abstract]2020 Oct;180:114126. PMID: 32603665 -
Cancer Biol Ther
PCBP1 regulates LIFR through FAM3C to maintain breast cancer stem cell self-renewal and invasiveness. [Abstract]2023 Dec 31;24(1):2271638. PMID: 37927213 -
Cell Biol Toxicol
The mtDNA-STING pathway plays an important role in both navitoclax- and S63845-induced autophagy and enhances cell death. [Abstract]2023 Dec;39(6):2821-2839. PMID: 37002446 -
Cell Oncol (Dordr)
OTUD1 downregulates PD-L1 expression by deubiquitinating STAT3 and promotes the immune response in CcRCC. [Abstract]2025 Jun 12. PMID: 40506611 -
Int Immunopharmacol
PLD2 deletion alleviates disruption of tight junctions in sepsis-induced ALI by regulating PA/STAT3 phosphorylation pathway. [Abstract]2023 Jan:114:109561. PMID: 36700766
STAT3-IN-1 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2023 Jan:114:109561. [Abstract]
STAT3-IN-1 (5 µM) attenuates PA-induced degradation of endothelial TJs by inhibiting phosphorylation of STAT3 in HUVECs.
-
Cell Biol Int
Tumor-associated macrophage-derived CCL5 promotes chemotherapy resistance and metastasis in prostatic cancer. [Abstract]2021 Oct;45(10):2054-2062. PMID: 34003531 -
Solvent & Solubility
DMSO : 125 mg/mL (262.86 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 6.25 mg/mL (13.14 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 6.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1029 mL | 10.5146 mL | 21.0292 mL | 52.5729 mL |
| 5 mM | 0.4206 mL | 2.1029 mL | 4.2058 mL | 10.5146 mL | |
| 10 mM | 0.2103 mL | 1.0515 mL | 2.1029 mL | 5.2573 mL | |
| 15 mM | 0.1402 mL | 0.7010 mL | 1.4019 mL | 3.5049 mL | |
| 20 mM | 0.1051 mL | 0.5257 mL | 1.0515 mL | 2.6286 mL | |
| 25 mM | 0.0841 mL | 0.4206 mL | 0.8412 mL | 2.1029 mL | |
| 30 mM | 0.0701 mL | 0.3505 mL | 0.7010 mL | 1.7524 mL | |
| 40 mM | 0.0526 mL | 0.2629 mL | 0.5257 mL | 1.3143 mL | |
| 50 mM | 0.0421 mL | 0.2103 mL | 0.4206 mL | 1.0515 mL | |
| 60 mM | 0.0350 mL | 0.1752 mL | 0.3505 mL | 0.8762 mL | |
| 80 mM | 0.0263 mL | 0.1314 mL | 0.2629 mL | 0.6572 mL | |
| 100 mM | 0.0210 mL | 0.1051 mL | 0.2103 mL | 0.5257 mL |
STAT3-IN-1 Related Classifications
HY-100753 Related Classifications
Powered by Bioz